💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pyrazinamide

CHEMBL614 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
123.1 g/mol
LogP
-0.6
Phase
4

Pyrazinamide is a first-line antimycobacterial prodrug that is converted by mycobacterial pyrazinamidase to pyrazinoic acid, which disrupts the bacterial membrane potential and interferes with fatty acid biosynthesis and energy metabolism in Mycobacterium tuberculosis. It is a key component of standard short-course antituberculosis regimens, particularly valuable for its sterilizing activity against semi-dormant bacilli in acidic environments.

Khối lượng phân tử

123,1100 g/mol

LogP

-0,60

TPSA

68,90 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Chronic Obstructive Pulmonary Disease Deep Vein Thrombosis / Pulmonary Embolism Hypertension HIV/AIDS Hepatitis C Tuberculosis

Cơ chế tác dụng

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
NC(=O)c1cnccn1

                

                

                
                

                    
InChI

                    
InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)

                

                

                

                    
                    

                        
Molecular Formula

                        
C5H5N3O

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
Liên kết có thể quay

                        
1

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
9

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
Pyrazinamide is a first-line antimycobacterial prodrug that is converted by mycobacterial pyrazinamidase to pyrazinoic acid, which disrupts the bacterial membrane potential and interferes with fatty acid biosynthesis and energy metabolism in Mycobacterium tuberculosis. It is a key component of standard short-course antituberculosis regimens, particularly valuable for its sterilizing activity against semi-dormant bacilli in acidic environments.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Pyrazinamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL614.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 1046.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.